We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+186.12%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$147M
AUM Growth
+$50.5M
Cap. Flow
-$12.7M
Cap. Flow %
-8.64%
Top 10 Hldgs %
79.38%
Holding
35
New
7
Increased
4
Reduced
6
Closed
5

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$6.2M
2
TERN
Terns Pharmaceuticals
TERN
+$3.1M
3
NERV icon
Minerva Neurosciences
NERV
+$2.63M
4
TNGX icon
Tango Therapeutics
TNGX
+$2.44M
5
DSGN icon
Design Therapeutics
DSGN
+$1.18M

Top Sells

Rank Stock Value
1
TRML
Tourmaline Bio
TRML
+$12.8M
2
CDTX
Cidara Therapeutics
CDTX
+$8.47M
3
INSM icon
Insmed
INSM
+$2.32M
4
ASND icon
Ascendis Pharma A/S
ASND
+$1.95M
5
KRYS icon
Krystal Biotech
KRYS
+$1.87M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
26
Revolution Medicines
RVMD
$42.4B
$670K 0.45%
8,411
– –
LBRX
27
LB Pharmaceuticals
LBRX
$1.37B
$668K 0.45%
30,000
– –
KTTA icon
28
Pasithea Therapeutics
KTTA
$15.1M
$581K 0.39%
+450,000
New +$395K
UNCY icon
29
Unicycive Therapeutics
UNCY
$140M
$346K 0.24%
59,985
– –
NUVB.WS
30
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$30K 0.02%
90,832
– –
ASND icon
31
Ascendis Pharma A/S
ASND
$16.7B
– –
-9,792
Closed -$1.95M
COGT icon
32
Cogent Biosciences
COGT
$7.21B
– –
-102,907
Closed -$1.48M
FULC icon
33
Fulcrum Therapeutics
FULC
$289M
– –
-57,141
Closed -$526K
KRYS icon
34
Krystal Biotech
KRYS
$9.59B
– –
-10,573
Closed -$1.87M
TRML
35
DELISTED
Tourmaline Bio
TRML
– –
-268,451
Closed -$12.8M
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM

Acuta Capital Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Acuta Capital Partners held 35 positions worth $147M, up 52% from $96.8M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Acuta Capital Partners withdrew a net $12.7M in Q4 2025, closing 5 positions and reducing 6 holdings. Its most notable exit was Tourmaline Bio, an estimated $12.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in Minerva Neurosciences worth $2.85M.

  • Acuta Capital Partners's largest Q4 2025 buy was Minerva Neurosciences: 709,500 shares worth $2.85M.
  • Acuta Capital Partners added most to Praxis Precision Medicines in Q4 2025, an estimated $6.2M increase.
  • Acuta Capital Partners's biggest Q4 2025 reduction was Cidara Therapeutics, cutting an estimated $8.47M.
  • Acuta Capital Partners fully exited Tourmaline Bio in Q4 2025, selling an estimated $12.8M.
  • Acuta Capital Partners's ten largest holdings make up 79% of its $147M portfolio in Q4 2025.
  • Acuta Capital Partners opened 7 new positions and closed 5 in Q4 2025.
  • Acuta Capital Partners's portfolio value rose 52% quarter-over-quarter to $147M.

Based on Acuta Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.